We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01629732
Recruitment Status : Withdrawn
First Posted : June 28, 2012
Last Update Posted : May 9, 2014
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the effectiveness of BMS-986094 and Daclatasvir (DCV) when given in combination with or without Ribavirin

Condition or disease Intervention/treatment Phase
Hepatitis C Virus Drug: Daclatasvir Drug: BMS-986094 Drug: Ribavirin Drug: Placebo for BMS-986094 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C
Study Start Date : March 2013
Estimated Primary Completion Date : February 2014
Estimated Study Completion Date : June 2014

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo

Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)

Re-Randomized Arm 1 to Arm 1a and 1b (additional 12 weeks treatment)

 Drug: Daclatasvir
Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
Other Name: BMS-790052 (DCV)

Drug: BMS-986094
Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks

Drug: Placebo for BMS-986094
Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
Experimental: Arm 2: Daclasasvir + BMS-986094 (200 mg)

Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)

Re-Randomized Arm 2 to Arm 2a and 2b (additional 12 weeks treatment)

 Drug: Daclatasvir
Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
Other Name: BMS-790052 (DCV)

Drug: BMS-986094
Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks
Experimental: Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin

Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)

Re-Randomized Arm 3 to Arm 3a and 3b (additional 12 weeks treatment)

 Drug: Daclatasvir
Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
Other Name: BMS-790052 (DCV)

Drug: BMS-986094
Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks

Drug: Ribavirin
Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
Other Name: Copegus®

Drug: Placebo for BMS-986094
Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
Experimental: Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin

Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)

Re-Randomized Arm 4 to Arm 4a and 4b (additional 12 weeks treatment)

 Drug: Daclatasvir
Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
Other Name: BMS-790052 (DCV)

Drug: BMS-986094
Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks

Drug: Ribavirin
Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
Other Name: Copegus®
Experimental: Arm 5: Daclasasvir + BMS-986094 (200 mg)
Genotype 1 PI-failure subjects
 Drug: Daclatasvir
Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
Other Name: BMS-790052 (DCV)

Drug: BMS-986094
Capsule, Oral, 200 mg, Once daily, 24 Weeks
Experimental: Arm 6: Daclasasvir + BMS-986094 (200 mg)
Genotype 4 naive subjects
 Drug: Daclatasvir
Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
Other Name: BMS-790052 (DCV)

Drug: BMS-986094
Capsule, Oral, 200 mg, Once daily, 24 Weeks
Experimental: Arm 7: Daclasasvir + BMS-986094 (200 mg)
Genotype 2/3 NR/relapse Subjects
 Drug: Daclatasvir
Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
Other Name: BMS-790052 (DCV)

Drug: BMS-986094
Capsule, Oral, 200 mg, Once daily, 24 Weeks


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Proportion of subjects with SVR4 defined as HCV RNA < LOQ (25 IU/mL; detectable or undetectable) at 4 weeks post treatment to be evaluated in GT1 (naive and NR) subjects randomized to the 12-week treatment arm (arms 1a, 2a, 3a, 4a) [ Time Frame: Follow up Week 4 ]
    • SVR = Sustained virologic response
    • HCV = Hepatitis C virus
    • RNA = Ribonucleic acid
    • LOQ = Limit of quantitation


Secondary Outcome Measures :
  1. Proportion of treated subjects with SVR4 in genotype (GT) 1 naive and non-responder (NR) subjects randomized to the 24-week treatment arms (arms 1b, 2b, 3b, 4b) [ Time Frame: Follow up Week 4 (SVR4) ]
  2. Proportion of treated subjects with SVR4 in genotype 1 protease inhibitor (PI)failures, genotype 4 naive, and genotype 2/3 NR/relapse subjects (arms 5, 6, 7) [ Time Frame: Follow up Week 4 (SVR4) ]
  3. Proportion of treated subjects in each study population (GT1 naive, GT1 NR, or GT1 PI-failure, GT4 naive, GT2/3 NR/relapse), for each regimen and duration, who achieve HCV RNA < LOQ at post-treatment [ Time Frame: Post-treatment Week 2 (SVR2), Week 8 (SVR8), Week 12 (SVR12), Week 24 (SVR24), and Week 36 (SVR36, for the 12 week arms) ]
  4. Proportion of treated subjects in each study population, by regimen, who achieve HCV RNA < LOQ (detectable/undetectable) [ Time Frame: Weeks 1, 2, 4, 6, 8, 12 and End of Treatment (Week 12 or 24) ]
  5. Proportion of subjects in each study population, be regimen, who achieve HCV RNA undetectable [ Time Frame: Weeks 1, 2, 4, 6, 8, 12 and End of Treatment (Week 12 or 24) ]
  6. Safety and tolerability of BMS-986094 and DCV ± RBV as measured by the frequency of deaths, serious adverse events (SAEs), discontinuations due to Adverse Events (AEs), and severity Grade 3/4 laboratory abnormalities [ Time Frame: Up to post treatment Week 36 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and females, ≥ 18 years of age
  • Subjects chronically infected with Hepatitis C virus (HCV) genotype 1,2,3 or 4
  • HCV RNA viral load ≥ 10,000 IU/mL
  • Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped at approximately 25% of treated population)
  • Body Mass Index (BMI) of 18 to 35 kg/m2
  • Seronegative for Hepatitis C virus (HIV) and Hepatitis B

Exclusion Criteria:

  • Evidence of decompensated liver disease
  • Evidence of medical condition contributing to chronic liver disease other than HCV
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01629732


Locations
Layout table for location information
United States, Florida
Local Institution
Orlando, Florida, United States, 32804
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT01629732    
Other Study ID Numbers: AI472-007
2012-002519-24 ( EudraCT Number )
First Posted: June 28, 2012    Key Record Dates
Last Update Posted: May 9, 2014
Last Verified: May 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Infections
Enterovirus Infections
Picornaviridae Infections
 RNA Virus Infections
Blood-Borne Infections
Communicable Diseases
Flaviviridae Infections
Hepatitis, Chronic
Ribavirin
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents